BioCryst Pharmaceuticals (BCRX) reset expectations for 2026 after raising its full year revenue outlook, supported by licensing income, international partner orders, and continued Orladeyo momentum, including new pediatric formulations.
Recent trading tells a mixed story for BioCryst Pharmaceuticals. The 1 day share price return declined 1.31% and the 90 day share price return is down 28.90%. However, the 1 year total shareholder return of 4.15% and 3 year total shareholder return of 41.54% point to momentum that has built over a longer stretch, despite a softer few months around the latest guidance and earnings news.
Scan BioCryst Pharmaceuticals alongside other rare disease and high-potential healthcare stories by tracking our hand picked 20 high quality undiscovered gems that investors are already watching.
BioCryst Pharmaceuticals now trades well below recent highs after a sharp 90 day pullback, even as guidance and Orladeyo traction reset the story. Investors may be considering whether it makes more sense to lean in here or wait for a cleaner entry.
Most Popular Narrative: 63% Undervalued
On the analyst consensus Narrative on Simply Wall St, BioCryst Pharmaceuticals screens as materially undervalued, with a fair value estimate of $20.55 against the last close at $7.53. That gap rests on explicit assumptions about earnings power, cash generation, and how the market might price those profits.
The main thing that has to go right is successful execution of the HAE franchise plan, including continued ORLADEYO adoption, pediatric and global expansion, and a smooth path for navenibart through late stage trials and partnering.
The numbers imply the share price reflects a cautious view on how much value BioCryst Pharmaceuticals can ultimately realise from its HAE franchise, external rare disease pipeline, and current level of profitability.
See why 28 investors see BioCryst Pharmaceuticals as 63% undervalued.
Result: Fair Value of $20.55 (UNDERVALUED)
Still, this BioCryst Pharmaceuticals story depends heavily on ORLADEYO holding share against future oral HAE rivals and on profitability trends that currently benefit from one off inventory and licensing boosts.
Find out about the key risks to this BioCryst Pharmaceuticals narrative.
Next Steps
Mixed views like this around BioCryst Pharmaceuticals only matter if you test them against the numbers yourself. Step through the data, weigh both sides, and then drill into the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond BioCryst Pharmaceuticals?
You do not need to stop at BioCryst Pharmaceuticals. Use the Simply Wall St Screener to line up fresh opportunities, compare setups side by side, and pressure test your portfolio.
- Target potential mispricings by scanning a focused list of quality candidates using the 35 high quality undervalued stocks that could warrant a closer look.
- Prioritise staying power in tougher conditions by lining up a list of solid balance sheet and fundamentals (24 results) that can support operations through a wide range of scenarios.
- Lock in more dependable portfolio income by reviewing a curated set of 5 dividend fortresses that already clear a 5% yield hurdle.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com